FG020326, a Novel Third Generation P-glycoprotein Inhibitor

Liwu Fu,Liming Chen,Yong-ju Liang,Xiaoping Yang

IF: 11.2

2007-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 2281 Purpose: Successful chemotherapy is limited by multidrug resistance (MDR) phenomenon mainly mediated by the overexpression of P-glycoprotein 170 termed as P-gp that serves as an efflux pump removing various cytostatic drugs from the MDR cells. This study was designed to investigate FG020326, a novel imidazole derivative, reversing MDR in vitro and in vivo. Materials and Methods: We used tetrazolium (MTT) assay in combination with doxorubicin (Dox) accumulation study to evaluate the ability of FG020326 to reverse drug resistance in vitro in two human MDR cell lines MCF-7/adr, KBv200 and their parental drug sensitive cell lines MCF-7 and KB. KBv200 cell xenograft model was established to investigate the effect of FG020326 on reversing MDR in vivo . The function, expression and [3H]azidopine photoaffinity labeling of P-gp were measured to explore the mechanism of reversing MDR. The activity of CYP 3A4 was examined by HPLC with nifedipine as substrate of CYP 3A4. FG020326 pharmacokinetic and pharmacokinetic interaction with Dox in mice was investigated by HPLC. Results: FG020326 significantly enhanced the cytotoxicity of Dox and vincristine (VCR) to MCF-7/adr and KBv200, respectively. FG020326 exhibited at least 3-fold strong reversal MDR activity as positive control agent, verapamil. FG020326 also increased the intracellular accumulation of Dox in MCF-7/adr cells but it didn’t affect that in drug sensitive MCF-7 cells. In mice bearing the MDR KBv200 cell xenografts, co-administration of FG020326 significantly enhanced antitumor activity of VCR (inhibited rate is 54.2%) without increasing the toxicity. KBv200 cells treated by FG020326 results in the enhancement of Rhodamne 123 accumulation, the decrease of the expression of P-gp and the inhibition of [3H]azidopine photoaffinity labeling in concentration-dependent manner. FG020326 did not inhibit the activity of CYP 3A4 until 50μmol/L. FG020326 could expose the mice enough high plasma concentration required for effectiveness while did not affect on the pharmacokinetics of anticancer drug such as Dox. Conclusions : FG020326 was a potent MDR modulator not only in vitro but also in vivo and exhibited the characterizations of the third generation MDR modulator.